key: cord-0959559-b53i8fpy
authors: Lu, Jia; Yin, Qiangling; Pei, Rongjuan; Zhang, Qiu; Qu, Yuanyuan; Pan, Yongbing; Sun, Lina; Gao, Ding; Liang, Cuiqin; Yang, Jingwen; Wu, Wei; Li, Jiandong; Cui, Zongqiang; Wang, Zejun; Li, Xinguo; Li, Dexing; Wang, Shiwen; Duan, Kai; Guan, Wuxiang; Liang, Mifang; Yang, Xiaoming
title: Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants
date: 2022-02-18
journal: Virol Sin
DOI: 10.1016/j.virs.2022.02.005
sha: 8fa04d5c427c8e9379528832c0f0f9580aebaf22
doc_id: 959559
cord_uid: b53i8fpy

Multiple new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have constantly emerged, as the delta and omicron variants, which have developed resistance to currently gained neutralizing antibodies. This highlights a critical need to discover new therapeutic agents to overcome the variants mutations. Despite the availability of vaccines against coronavirus disease 2019 (COVID-19), the use of broadly neutralizing antibodies has been considered as an alternative way for the prevention or treatment of SARS-CoV-2 variants infection. Here, we show that the nasal delivery of two previously characterized broadly neutralizing antibodies (F61 and H121) protected K18-hACE2 mice against lethal challenge with SARS-CoV-2 variants. The broadly protective efficacy of the F61 or F61/F121 cocktail antibodies was evaluated by lethal challenge with the wild strain (WIV04) and multiple variants, including beta (B.1.351), delta (B.1.617.2), and omicron (B.1.1.529) at 200 or 1000 TCID(50), and the minimum antibody administration doses (5–1.25 mg/kg body weight) were also evaluated with delta and omicron challenge. Fully prophylactic protections were found in all challenged groups with both F61 and F61/H121 combination at the administration dose of 20 mg/kg body weight, and corresponding mice lung viral RNA showed negative, with almost all alveolar septa and cavities remaining normal. Furthermore, low-dose antibody treatment induced significant prophylactic protection against lethal challenge with delta and omicron variants, whereas the F61/H121 combination showed excellent results against omicron infection. Our findings indicated the potential use of broadly neutralizing monoclonal antibodies as prophylactic and therapeutic agent for protection of current emerged SARS-CoV-2 variants infection.

The mAbs could be detected in lungs shortly after nasal spray and kept in the lungs for a long time. 48 49 High dose mAbs nasal delivery could fully prophylactic protection mice from omicron lethal challenged. 50 51

Significant enhancement of broadly neutralizing activity against variants were confirmed in F61 and H121 52 combination use. 53 J o u r n a l P r e -p r o o f emerged, as the delta and omicron variants, which have developed resistance to currently gained neutralizing 56 antibodies. This highlights a critical need to discover new therapeutic agents to overcome the variants mutations. 57

Despite the availability of vaccines against coronavirus disease 2019 (COVID-19), the use of broadly 58 neutralizing antibodies has been considered as an alternative way for the prevention or treatment of SARS-CoV-59 2 variants infection. Here, we show that the nasal delivery of two previously characterized broadly neutralizing 60 antibodies (F61 and H121) protected K18-hACE2 mice against lethal challenge with SARS-CoV-2 variants. 61

The broadly protective efficacy of the F61 or F61/F121 cocktail antibodies was evaluated by lethal challenge 

The F61 antibody was conjugated with Alexa Fluor 70 dye for in vivo imaging studies. Briefly, 1.78 mg/mL 159 solution of F61 in phosphate-buffered saline (PBS; pH 7.4) was reacted with Alexa Fluor 750 succinimidyl ester 160 (AF750-NHS; Thermo Fisher Scientific) in the presence of 3% dimethyl sulfoxide and 10% sodium bicarbonate 161 buffer (v/v, pH 8.3) at a molar ratio of 1:10 (protein to fluorescent probe) at room temperature for 1 h. Unreacted 162 dye was removed by dialysis, and the labeled antibody was washed in PBS and concentrated with an Amicon 163 ultra centrifugal filter unit (molecular weight cut off: 10 kDa). All procedures were performed under dimmed 164 light. C57BL/6N mice (6-8 weeks old, male; GemPharmatech Co., Ltd. Company) were anesthetized by 165 inhalation of 2% isoflurane and placed in a supine position. The mice were administered Alexa Fluor 750-166 labeled F61 into both nostrils using a fine pipet tip (50 μL total) to achieve a final antibody dose of 1.25, 5, or 167 10 mg/kg. The mice were then imaged at 2 min, 16 min, 2 h, 24 h, 48 h, 72 h, and 96 h after administration 168 (fluorescence excitation wavelength = 740 nm, emission wavelength = 790 nm, auto-exposure setting, n = 4 169 mice/group) using an IVIS Lumina XRMS Imager (Perkin Elmer). At the time of euthanasia, the heart, lungs, 170 liver, spleen, kidneys, brain, jejunum, urocyst, and nasal cavities were excised and imaged. Regions of interest 171 (ROIs) were drawn, and the average radiant efficiency ([p/s/cm 2 /sr] / [μW/cm 2 ]) was measured. This parameter 172 represents the sum of the radiance from each pixel inside the ROI divided by the number of pixels. All images 173 were processed using Living Image software (Perkin Elmer), and the same fluorescence threshold was applied 174 for group comparison. 175 176

Mouse protection experiments were approved by the Experimental Animal Welfare and Ethical Review Board 

Tissue homogenates were generated using the Tissue Lyzer II (Qiagen, Gaithersburg, MD, USA). Briefly, 1000 201 µL PBS was added to each sample (lungs, 0.01-0.04 g) along with Tungsten carbide 3 mm beads (Qiagen). 202

Samples were homogenized at a speed of 10 Hz for 10 min and then centrifuged at 15,000 × g for 10 min. 203

Supernatants were collected, aliquoted, and stored at −80°C until further analysis. 

Total RNA was extracted from tissues homogenates of lungs using an RNA/DNA Purification Kit (Magnetic 207 Bead) (cat no. DA0623; Daan Gene Co., Ltd., China), and qRT-PCR was performed using a Detection Kit for 208 2019-nCoV (PCR-Fluorescence) (Fast) (cat no. DA0992; Daan Gene Co., Ltd.) following the manufacturer's 209 instructions. Samples were processed in duplicate using the following cycling protocol: 50 °C for 2 min, 95 °C 210 for 2 min, followed by 40 cycles at 95 °C for 5 s and 60 °C for 10 s. Viral RNA concentrations (copies/mL) in 211 the lungs of mice were determined using RNA standards for SARS-CoV-2 (Bdsbiotech Co. Ltd., Guangzhou, 212 China). The qRT-PCR results were read according to the Daan Kit criteria, the negative results in this manuscript 213 description mean no signal detected (0 copy) or the CT values of both N and ORF genes were over 38, 214 corresponding viral RNA copies were under the limitation of the detection (LOD, 10 2.7 copies/mL). 215 216

Autopsies were performed in an animal biosafety level 3 laboratory. Lungs were placed in 10% buffered 218 formalin solution and fixed for at least 72 h, and paraffin sections (3-4 μm in thickness) were prepared routinely. 219

Hematoxylin and eosin staining was used to identify histopathological changes in the lungs. The histopathology 220 of the lung tissue was observed by light microscopy. 

To determine the Bio-distribution of antibodies in mice after intranasal administration, different doses of Alexa 229

Fluor® 750 labeled F61 was delivered and the levels of fluorescently labeled antibody were determined at 230 different time points after antibody administration. Whole-body images showed that 2 min after intranasal 231 administration, the monoclonal antibodies were mainly distributed in the nasal passages for the three 232 monoclonal antibody administration groups. In the 5 and 10 mg/kg group, the monoclonal antibodies began to 233 enter the lungs at 16 min after administration (Fig. 1A) . At 24 h after administration, the monoclonal antibodies 234 were mainly distributed in the lungs (Fig. 1B , E, H). Notably, ex vivo images showed that labeled monoclonal 235 antibodies were still detected in the lungs at 48 h after administration in the 1.25 mg/kg group (Fig. 1D , G, J). 236 We then further assessed the dynamic distributions of antibodies in mice after intranasal administration of 237 the lowest dose of monoclonal antibody. The fluorescence signals in mice after administration was imaged and 238 quantified. In the 2 h group, the antibody was mainly distributed in the lungs (209.52 × 10 8 ± 122.93× 10 8 239

[p/s/cm 2 /sr] / [μW/cm 2 ] ), followed by the liver (9.46 × 10 8 ± 2.62× 10 8 ) and nasal cavity (8.71 × 10 8 ± 6.34 × 240 10 8 ; Fig. 1K , O). In the 24 h group, the antibody levels in the lungs, liver, and nasal cavities decreased (40.78%, 241 29.30%, and 81.51% respectively), and the antibody was detected in the urocyst (5.22 × 10 8 ± 2.83 × 10 8 ; Fig.  242 1L, P). In the 48 h group, the antibody levels in the lungs, liver, and nasal cavities showed persistent decreases 243 (76.05%, 61.22%, and 91.90% respectively; Fig. 1M , Q). In the 96 h group, monoclonal antibodies were still 244 detected in the lungs (23.46 × 10 8 ± 13.55 × 10 8 ) and liver (3.51 × 10 8 ± 0.69 × 10 8 ) and were barely detectable 245 in other organs (Fig. 1N, R) . 1.351; Fig. 2E , G); none of the mice in the PBS group survived ( Fig. 2A, C , 257 E, G). We also found that all antibody groups protected K18-hACE2 mice against body weight loss caused by 258 WIV04 (Fig. 2B, D) and B.1.351 (Fig. 2F, H) . The body weights of mice in the PBS group were significantly 259 reduced beginning on day 4, and body weights continued to decrease until death. The body weights of mice in on days 4 and 5 post infection (P < 0.05; Fig. 2B , D, F, H). Note that we concluded that the death of two mice 262 receiving 1000 TCID50 WIV04 challenge (Fig. 2C, F61) was not related to the virus (two mice fought, cut off 263 their tails and dead at day 6), because the body weight of the mouse increased. 264 We then evaluated viral loads in the lungs of virus-challenged mice and pathogenic changes. The results 265 showed that following 200 TCID50 WIV04 challenge, the average viral RNA load in the lungs of mice in the 266 PBS group was 10 5 copies/mL lung tissue, whereas viral RNA was negative in the antibody groups (P < 0.05; 267 Fig. 3A-a) . With 1000 TCID50 challenge, the average viral RNA load in the PBS group reached 10 8 copies/mL, 268 whereas that in the antibody groups remained low (P < 0.05; Fig. 3A-b) . Similar results were observed for 269 challenge with the beta variant (B.1.351); regardless of the dose, the average viral RNA load in the control 270 groups was 10 7 -10 8 /mL in lung tissues, whereas that in the antibody groups was negative (Fig. 3A-c, F61) or 271 low (10 3~1 0 4 copies/mL; P < 0.05; Fig 3A- infiltration in the alveoli (Fig 3B-a, -d, -g, -j) . 

We next determined whether F61 alone or the F61/H121combination could confer in vivo protection against the 280 delta variant of SARS-CoV-2. In challenge with 200 TCID50 delta variant, high (10 and 20 mg/kg body weight) 281 and low doses (5 mg/kg body weight) of F61 or F61/H121 neutralizing monoclonal antibodies provided 282 complete protection against death and blocked body weight loss (P < 0.05; Fig. 4A , B, left and middle). 283

Administration of 1.25 mg/kg F61 or F61/H121 also significantly protected mice from body weight loss and 284 death, except in one mouse (Fig. 4A, B middle) . Furthermore, viral RNA copies in the control group reached 285 10 9 copies/mL in lung tissues, whereas those in the antibody groups, including the minimum dose antibody 286 group, were significantly reduced or undetectable (under the limitation of detection, 10 2.7 copies/mL) (Fig. 4A,  287 

In challenge with 1000 TCID50 delta variant (later to be known equivalent to 1000 lethal dose 50% [LD50], 289 data not shown), the high-dose antibody groups (20 mg/kg) were fully protected from the death and showed 290 absence or a significant reduction of viral RNA in the lungs; the low-dose (5 mg/kg) were also protected with 291 the survival rate of 83% (5/6) (Fig. 4D, E, left) ; only the minimum group (1.25 mg/kg) loss the body weight and 292 the mice survival rate reduced to 33% (2/6) for F61 group and 50% (3/6) for F61+H121 group (Fig. 4D, E,  293 middle and left). 294 the brain tissue homogenates of these mice (reach to 10 9.8 copies/mL) were extremely higher than the copies in 299 the lung tissue homogenates compared with the PBS group, the viral RNA copies in brains of both F61 and 300 F61/H121 antibody groups were reduced (data not shown). 301 Histological analysis showed that almost all alveolar septa and cavities were normal in the antibody 302 administration groups following challenge with 200 or 1000 TCID50 delta variant, and only mild lung damage 303 was observed in the group administered 1.25 mg/kg monoclonal antibody. By contrast, mice in PBS control 304 group showed severe lung damage, characterized by diffuse alveolar damage, including thickening of the 305 alveolar septa, and extensive immune infiltration in the alveoli (data not shown). 306 307

In November 2021, a new variant of SARS-CoV-2, the omicron (B.1.1.529), was reported from South Africa. 309

This variant spreads rapidly, becoming the current major epidemic variant. Therefore, we next performed 310 similar experiments using the omicron variant. Importantly, regardless of the dose or monoclonal antibody type, 311 antibody treatment conferred protection against lethal challenge in K18-hACE mice inoculated with 200 TCID50 312 omicron variant (Fig 5A left) , and body weights of mice remained normal throughout the experiments (Fig. 5A  313 middle). Moreover, viral RNA in the lungs of mice was not detectable when the F61/H121 combined was used 314 (Fig. 5A right) . However, in the high-dose omicron challenge (1000 TCID50 or 200 LD50), although high-dose 315 antibody administration (20 mg/kg) protected mice from death and body weight loss, low-dose administration 316 (5 mg/kg) only partially protected mice (Fig. 5B left and middle) , and viral RNA was detected in all dead or 317 surviving mice. Despite this, the F61/H121 combination treatment significantly reduced viral RNA loads 318 (10 3~1 0 4 copies/mL) in the lungs of mice compared with that in the PBS groups (10 7 copies/mL, Fig. 5B, right) . administered at a high dose (20 mg/kg), and significant prophylactic protection was also observed in the low-327 dose group (5 mg/kg). Additionally, F61/H121 administration also showed protection against the omicron 328 variant when applied at a high dose. Thus, the broadly neutralizing monoclonal antibodies used in our study 329 (F61 and H121) could be applied as potential prophylactic and therapeutic agents against current and emerging 330

Our reliable findings showed that F61 and H121 had good protective effects, and strong correlations were 332 observed among the evaluated parameters (i.e., body weight loss, survival rate, and viral load). In the control reliability of antibody evaluation results. In our study, totally we used 138 mice K18-hACE2 (6 batches of mice), 337 only two mice died abnormally with no weight loss as we described in the result (Fig. 2C, F61 20 mg/kg group 338 with 1000 TCID50 WIV04 challenge). As we showed in the result (Fig. 4D and E) , the tested K18-hACE2 mice 339 in the low antibody dose groups with 1000 TCID50 delta variant challenge have low RNA copies in lungs but 340 high copies in brains. That might because of the abnormal high expression of ACE2 in brain. Even so, F61 or 341 F61/H121 cocktail protected most of tested mice (5/6) from the high dose death challenge at a low dose (5 342 mg/kg body weight), and partial protection at the minimum antibody administration groups. 343

For the challenge of recent emerged omicron variant, the antibodies also showed effective protection, in 344 particular use the F61/H121 cocktail bivalent antibodies. As we described previously (Qu et al., 2021) , F61 345 recognizes a competitive epitope in ACE2-RBD binding domain, which may classified into class 1 neutralizing 346 antigenic site (Barnes et al., 2020) . H121 binds to an ACE2 non-competitive epitope located in a conserved side 347 of RBD, which is closed to the class 4 antigenic site (Barnes et al., 2020) . F61 directly blocks the virus binding 348 with ACE2, while H121 may use mechanisms other than directly interfering with ACE2 binding. The cocktail 349 of these two high affinity neutralizing antibodies could exhibit pan-sarbecovirus neutralization capacity to 350 against most of SARS-CoV2 variants including omicron variants. 351 Furthermore, human immunoglobulin G antibodies were used instead of mouse antibodies in this study, 352 which may have interfered with antibody function owing to interspecies difference (Yamin et al., 2021) . 353 Therefore, antibody evaluation in nonhuman primate animal models is essential for subsequent studies. In In this study, we found that the broadly neutralizing antibodies F61 and H121 could be detected in the 387 lungs shortly after intranasal administration and persisted in the lungs for a long time. Furthermore, we showed 388 that the two antibodies could be used as prophylactic drugs to prevent the transmission of SARS-CoV-2. Thus, 389

we speculated that our antibodies may also show good in vivo therapeutic effects. In summary, the two 390 antibodies evaluated in this study may be candidate therapeutic and preventive drugs with a wide range of 391 applications. Further studies are needed. 392 393

All the data generated during the current study are included in the manuscript. values represent means ± standard errors of the mean (n = 3 mice/group). Significant differences between the 526 antibody treatment group and negative control are shown. ns, P > 0.05; *, P < 0.05; **, P < 0.0001, as 527 determined by Student's t-tests.. 528 detected by qRT-PCR of K18-hACE2 mice treated with a low dose antibodies (5 mg/kg or 1.25 mg/kg; D for 549 F61, E for F61+H121 cocktail) via intranasal route before infection with 1000 TCID50 of delta variants. Viral 550 RNA loads were determine using qRT-PCR. Body weight curve values represent means ± standard errors of the 551 means (n = 3~6 mice/group). Significant differences between the antibody treatment group and negative control 552 are shown. All data points of virus load in the lungs are shown, along with the medians. ns, P > 0.05; *, P < 553 0.05; **, P < 0.0001, as determined by Student's t tests. Limit of detection (LOD), 500 copies/mL. 554 A, B) . Body weight curve values represent means ± standard errors of the means (n = 3~4 560 mice/group). Significant differences between the antibody treatment group and negative control are shown. All 561 data points for viral load in the lungs are shown, along with the medians. ns, P > 0.05; *, P < 0.05; **, P < 562 0.0001, as determined by Student's t-tests. Limit of detection (LOD), 500 copies/mL. 563

SARS-CoV-2 escape in vitro from a highly 421 neutralizing COVID-19 convalescent plasma

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Heavily mutated Omicron variant puts scientists on alert

Omicron escapes 427 the majority of existing SARS-CoV-2 neutralizing antibodies

Omicron Variant (B.1.1.529): Infectivity, vaccine breakthrough, and 429 antibody resistance

COVID-19 antibodies on trial

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug 433 Resist Updat

Receptor-binding domain of SARS-CoV spike 435 protein induces long-term protective immunity in an animal model

Food and Drug Administration (FDA) Emergency Use Authorization

Food and Drug Administration (FDA) FDA NEWS RELEASE. Coronavirus (COVID-19) Update: FDA Authorizes New 440

Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals

GISAID (2022) SARS-CoV-2 (hCoV-19) Mutation Reports

A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies

Receptor-binding domain of SARS-CoV spike protein 448 induces highly potent neutralizing antibodies: implication for developing subunit vaccine

The Omicron variant is highly resistant against antibody-mediated neutralization -452 implications for control of the COVID-19 pandemic

Exploiting mucosal immunity for antiviral vaccines

National Institutes of Health (NIH) (2021) COVID-19 Treatment Guidelines Panel

Roadmap to Valk, S.J., 2021. SARS-CoV-2 -neutralising monoclonal antibodies for treatment of COVID-19

Nasal delivery of an IgM offers broad protection from SARS-CoV-2 465 variants

Antibody-laden nasal spray could provide COVID protection and treatment

On the Calculation of TCID 50 for Quantitation of Virus Infectivity

Direct administration in the respiratory tract 471 improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies

Mapping Neutralizing and Immunodominant 474

Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Exhibits Broad Neutralization against SARS-CoV-2 and SARS-CoV-2 variants

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus 483

BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

Prospective mapping of viral mutations that 486 escape antibodies used to treat COVID-19

A 488 mouse model of SARS-CoV-2 infection and pathogenesis

Drug delivery systems: An 490 updated review

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

Subunit Vaccines against Emerging Pathogenic Human Coronaviruses

Escape from neutralizing antibodies by SARS-CoV-497 2 spike protein variants

World Health Organization (WHO) (2021) WHO Coronavirus Disease (COVID-19) Dashboard

World Health Organization (WHO) (2022) Tracking SARS-CoV-2 variants

Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy

We thanks Biosafety experts Dr. Donglin Song from Wuhan Institute of Virology, Chinese Academy of Sciences, 412Dr. Qiang Wei from Institute of Laboratory Animal Science, CAMS&PUMC for the biosafety assistance in all 413 mice experiments related to the wild or variants of SARS-CoV-2 virus challenges in ABSL-3 laboratory. This 

The authors declare that they have no conflict of interest. 418 419